第7章 主要メーカーの分析

第8章 中国のオルメサルタン市場の将来展望

市場規模予測

競合状況予測

図表一覧

※ このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Product Code: 1506191

Hypertension is the most dangerous factor that leads to the occurrence and resulting death of heart disease, cerebrovascular disease and kidney disease. According to the statistics of WHO, by 2030, nearly 23.6 million around the world will die of cardiovascular disease especially heart disease and apoplexy each year.

With the change of life styles brought about by economic development, the incidence of hypertension keeps growing in China. The number of hypertension patients is estimated to be 266 million with one in five adults suffering from it. Cardia-cerebrovascular disease is the leading cause of death in China and 50% of it relate to hypertension. Therefore, the effective control of hypertension and prevention of cardia-cerebrovascular disease has become an important health concern for health care workers and the public. On the other hand, patients need long-term pharmacotherapy for hypertension is a controllable disease.

In 1991, olmesartan medoxomil was successfully developed by Sankyo Pharmaceuticals Co., Ltd and was patented in many countries. In Apr. 2002, olmesartan medoxomil was approved by FDA to enter the American market in May. It has now become the best-selling drug in the world after it succeeded in the US market.

Compared with other ARBs, olmesartan medoxomil has distinctive pharmacokinetic properties. It develops fast after entering China with annual sales rising from CNY 4448 in 2010 to CNY 99.07 million and CAGR reaching up to 204.15%. Currently, there are three manufacturers of olmesartan in Chinese market: Shanghai Sankyo Pharmaceuticals Co., Ltd, Shanghai Sine Promod Pharmaceutical Co., Ltd and Beijing Winsunny Pharmaceutical Co., Ltd, among which Shanghai Sankyo Pharmaceuticals Co., Ltd has the biggest market share of 94.45% in 2014 with sales value reaching up to CNY 93.57 million in the same year.

With the increase of the incidence of cardiovascular disease and its number of cases, the market size of olmesartan is estimated to keep expanding in the next few years.

Readers can get at least the following information through this report:

market size of olmesartan in China

major manufacturers of olmesartan in the Chinese market and their market share

retail price of olmesartan in China

market outlook of olmesartan in China

The author suggests the following groups of people purchase this report: